Research programme: haem oxygenase-1 inhibitors - SelvitaAlternative Names: SEL303
Latest Information Update: 11 Nov 2014
At a glance
- Originator Selvita
- Mechanism of Action Decyclizing heme oxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Haematological malignancies; Solid tumours
Most Recent Events
- 11 Nov 2014 Early research in Solid tumours in Poland (unspecified route)
- 11 Nov 2014 Early research in Haematological malignancies in Poland (unspecified route)